CN108070644B - Diagnosis system for gestational hypertension - Google Patents
Diagnosis system for gestational hypertension Download PDFInfo
- Publication number
- CN108070644B CN108070644B CN201610981047.XA CN201610981047A CN108070644B CN 108070644 B CN108070644 B CN 108070644B CN 201610981047 A CN201610981047 A CN 201610981047A CN 108070644 B CN108070644 B CN 108070644B
- Authority
- CN
- China
- Prior art keywords
- misc
- feature
- trb
- cdr3
- unknown
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Abstract
The invention belongs to the field of immunology, and relates to application of a TRB-CDR3 detection reagent in preparation of a pregnancy hypertension diagnosis/screening agent, and a pregnancy hypertension diagnosis system. The diagnostic system contains a TRB-CDR3 nucleotide and/or amino acid sequence related to the pregnancy-induced hypertension disease. In the diagnostic system, different TRB-CDR3 nucleic acid sequences and/or amino acid sequences have different sensibility and specificity with the pregnancy-induced hypertension disease. By aligning the TRB-CDR3 sequence diversity of the test subject with the sequences in the diagnostic system for gestational hypertension of the present invention, gestational hypertension can be diagnosed/predicted/prognosed.
Description
Technical Field
The invention belongs to the field of immunology, and relates to an application of a TRB-CDR3 detection reagent and a diagnosis system in preparation of a pregnancy-induced hypertension diagnosis/screening reagent, and a pregnancy-induced hypertension diagnosis system.
Background
Hypertensive disorders of pregnancy (HDCP) are a general term for hypertensive disorders of pregnancy in women, and are classified into gestational hypertension, preeclampsia, eclampsia, chronic hypertension complicated with preeclampsia, and chronic hypertension. Preeclampsia is a serious type of hypertensive diseases in pregnancy, is a serious threat to the safety of mothers and infants, and is also one of the main causes of death of pregnant women, lying-in women and perinatal infants, and the death rate of the perinatal infants can reach 15% -30%. Basic research in recent years shows that the success of pregnancy depends on maternal-fetal immune balance, and once the immune balance is disordered, immunological rejection can be caused to cause preeclampsia and preeclampsia.
The immune system is an important system for the body to defend against pathogen invasion and immunoregulation, and the T Cell Receptor (TCR) is one of the most active immune macromolecules in the human genome. T Cell Receptors (TCRs) are molecules that produce antigens on the surface of T cells and mediate immune responses, and can be classified into two types, TCR α/β and TCR γ/δ, with peripheral blood T cells being predominantly T cells of TCR α/β. The TCR beta gene consists of four parts of gene segments of a variable region (V), a polytropic region (D), a binding region (J) and a constant region (C). During T cell development, V, D, J regions rearrange to form functional TCR-encoding genes, and different numbers of nucleotides between V-D and D-J are randomly inserted or deleted during rearrangement, and the inaccuracy of connection of the gene segments makes TCR expression diverse to recognize different antigens.
The diverse properties of TCR β (TRB) have been implicated in a variety of diseases, e.g. TCR β found in cancer patients is very similar and quite different from that found in healthy people. Cancer patients can be distinguished from healthy people by the TCR β diversity profile.
However, the relationship between the diversity of the TRB-CDR3 sequence and hypertensive disorders during pregnancy has never been studied before.
Disclosure of Invention
The invention aims to provide an application of a TRB-CDR3 detection reagent in preparing a pregnancy-induced hypertension diagnosis/screening agent.
The invention also aims to provide a diagnosis system for gestational hypertension, which contains TRB-CDR3 nucleotide and/or amino acid series related to gestational hypertension, and the sensitivity value of the pregnancy-induced hypertension can be obtained by comparing the TRB-CDR3 diversity sequence of a tester with the sequence of the diagnosis system.
The purpose of the invention is realized by the following technical means:
the invention provides an application of a TRB-CDR3 detection reagent in preparation of a pregnancy-induced hypertension diagnosis/screening agent.
The detection agent contains multiple PCR primers and a high-throughput sequencing primer.
The multiplex PCR primer is an HTCRI primer; the HTCRI primer comprises a first primer group and a second primer group.
The first primer set has a sequence selected from SEQ ID NOs: 1-26;
the second primer set has a sequence selected from SEQ ID NOs: 27, or a nucleotide sequence as set forth in figure 27.
The detection agent also contains polymerase.
Preferably, the polymerase is capable of amplifying fragments of several tens of kb; the extension speed is at least 1 kb/min; its robustness is such that on average no more than 1 error is introduced per kb.
The first diagnostic/screening agent was used to perform n-fold PCR amplification of the CDB-CDR3 region of the sample. Preferably, n ≧ 2, more preferably n ≧ 2.
The high-throughput sequencing primer is selected from SEQ ID NO: 28-29 of the sequence table
The invention also provides a diagnosis system for the gestational hypertension, which is also provided with an input module, a data comparison module and a result output module.
a. An input module: to input data information into the system, the data information being the TRB-CDR3 nucleotide sequence and/or amino acid sequence of the diagnostic subject;
b. a data comparison module: the data matching system is used for matching input data information with pre-stored data of the system, wherein the pre-stored data is relational data between one or more TRB-CDR3 sequences and pregnancy-induced hypertension risks;
c. a result output module: outputting the pregnancy hypertension risk data corresponding to the matching; when the input data information is matched with a certain pre-stored TRB-CDR3 sequence, the pregnancy period hypertension risk data corresponding to the pre-stored TRB-CDR3 sequence is the output result or the basis of the output result.
The diagnostic object is a pregnant person.
The pre-stored data in the data alignment module comprises one or more TRB-CDR3 nucleotide sequences, and/or comprises one or more TRB-CDR3 amino acid sequences;
further, the pre-stored data comprises SEQ ID NO: 30-59, one or more of the TRB-CDR3 nucleotide sequences: preferably, the pre-stored data comprises SEQ ID NO: 30-47 of one or more of the TRB-CDR3 nucleotide sequences; more preferably, said pre-stored data comprises SEQ ID NO: 30-35, or a TRB-CDR3 nucleotide sequence.
Further, the pre-stored data comprises SEQ ID NO: 60-89, one or more of the TRB-CDR3 amino acid sequences: preferably, the pre-stored data comprises SEQ ID NO: one or more of the TRB-CDR3 amino acid sequences of 60-77; more preferably, the pre-stored data comprises SEQ ID NO: 60-65, or a TRB-CDR3 amino acid sequence.
When the input data information is matched with a certain pre-stored TRB-CDR3 sequence, outputting a result as having a risk or a risk value; when the input data information matches a plurality of pre-stored TRB-CDR3 sequences, the output result is the highest risk value with a risk value.
When the input data information does not match any pre-stored TRB-CDR3 sequence, the output result is no risk or low risk.
The relationship data between the TRB-CDR3 sequence and the pregnancy-induced hypertension risk comprise one or more groups in the data in the following table 1: when groups 1-30 in the table below are present, there is a certain risk of disease.
Preferably, it must contain one or more of the following data sets 1-18, and when sets 1-18 are present, a higher risk of disease is present.
More preferably, it must contain one or more of the following group 1-group 6 data, and when group 1-group 6 is present, then a high risk of disease is present.
TABLE 1
The pregnancy hypertension diagnosis system of the present invention further comprises a detection means. The detection component is used for determining the TRB-CDR3 nucleotide sequence or amino acid sequence of a diagnosis object.
The detection means may employ any assay method including, but not limited to; one of genome and transcriptome level Q-PCR, genome and transcriptome level PCR, sequencing, DNA chip and protein chip.
In an exemplary embodiment of the invention, the method for detecting the detection component is high throughput sequencing, which specifically comprises the following steps:
s1, collecting peripheral blood of pregnant woman
S2, cell separation
S3.RNA extraction
S4.ARM-PCR amplification
S5, high-throughput sequencing
S6, bioinformatics analysis
In step S4, the primer of ARM-PCR is HTCRI primer.
The method for diagnosing/predicting/prognosing gestational hypertension by using the diagnosis system is characterized by comprising the following steps of:
i) sequencing the TRB-CDR3 sequence diversity of the peripheral blood of the test subject;
ii) inputting the TRB-CDR3 diversity sequence of the tester into the diagnosis system of the invention for comparison, and outputting the corresponding risk value/sensitive value of the disease by the diagnosis system according to the comparison result;
iii) if the subject is at risk of gestational hypertension, then they are included in the observation or treatment regimen.
The inventor finds that the characteristics of the immune repertoire of healthy pregnant women and severe and mild eclampsia patients have no obvious difference, and the number and the types of the CDR3 peptide fragments have no obvious difference. It is not obvious that the nucleic acid and/or amino acid sequences of certain TRB-CDR3 are closely related to gestational hypertension, and that the nucleic acid and/or amino acid sequences of different TRB-CDR3 show different sensitivity and specificity from disease. Therefore, these specific TRB-CDR3 sequences can be used as the basis for diagnosis/prediction/prognosis of pregnancy-induced hypertension, and when the testee contains the specific sequences in Table 1, the risk value or sensitivity value of the testee suffering from pregnancy-induced hypertension can be predicted. Notably, when SEQ ID NO: 30-47 and/or SEQ ID NO: 60-77, show higher specificity, indicating that the sequences can be used as indicative sequences of pregnancy-induced hypertension.
The inventor researches the relationship between the diversity of IGH-CDR3 sequences and the pregnancy-induced hypertension (Guochilong, Dumeng, Wang enkindi. pregnancy has an influence on the pregnant woman peripheral blood IGH-CDR3 immune repertoire [ J ]. China journal of family planning, 24(5):292.), but does not find an IGH-CDR3 peptide segment which is highly related and consistent with the pregnancy-induced hypertension, and proves that B lymphocytes lack specificity in the pregnancy-induced hypertension and are not the main pathogenesis of the disease. However, the inventor discovers that some TRB-CDR3 peptide fragments are ubiquitous in the pregnant hypertension patients through the research on T lymphocytes, so that the existence of the peptide fragments can be used for predicting and diagnosing the occurrence of the pregnant hypertension disease.
In addition, the invention discloses the influence of gestational hypertension on female TBR-CDR3 diversity and immunological characteristics, and provides an important basis for comprehensively disclosing the action and mechanism of immune tolerance in the pregnancy process.
Drawings
FIG. 1TRB-CDR3 region PCR product electrophoretogram
FIG. 2 principle of two PCRs for TRB-CDR3 region
FIG. 3 scheme for construction of TRB-CDR3 immune library
Detailed Description
The technical solutions of the present invention are further illustrated by the following specific examples, which do not represent limitations to the scope of the present invention. Insubstantial modifications and adaptations of the present invention by others of the concepts fall within the scope of the invention.
Example 1 construction of TRB-CDR3 test System for gestational hypertension
1) Blood sampling
After obtaining the informed consent, extracting 8-10ml of peripheral venous blood of the selected pregnant women, anticoagulating with heparin sodium, standing at room temperature, and completing the cell separation process within 4 hours
(the standard of the pregnant woman to be selected is that the normal pregnant woman is more than 39 weeks pregnant, the fetus and the pregnant woman are healthy, the pregnant woman has no history of blood transfusion, the pregnant woman has no related diseases during the gestation period and has no history of infection during the third month before admission; the standard of the pregnant woman to be selected for hypertension is that the systolic pressure is more than 140mmHg, the diastolic pressure is more than 90mmHg, the proteinuria is more than 0.3g/24h, or other general symptoms such as dizziness, edema and the like are accompanied)
2) Cell separation
a. Diluting 10ml of anticoagulated blood to 35ml by PBS, putting 15ml of lymphocyte separation liquid into another 50ml centrifugal tube, and placing the centrifugal tube at room temperature;
b. slowly adding the diluted whole blood to 15ml of lymphocyte separation liquid (taking care to ensure that the blood is still in the separation liquid after the blood sample is added, and not mixing the blood sample with the separation liquid), centrifuging at 20 ℃ for 25min at 400g (a spiral rotor, no brake, acceleration of 1-2, brake 0);
c. discarding the supernatant containing PBS and plasma, and aspirating the middle turbid cell layer into another clean 50ml centrifuge tube to ensure that all cells are aspirated and allow mixing of a portion of the lymphocyte separation fluid and plasma;
d. appropriate amount of PBS was added, centrifuged at 300g for 20min, the supernatant was discarded, and the cells were resuspended in 80ul of PBS, followed by transfer to 5 mltube. (if the liquid is still cloudy, it can be washed again and centrifuged once);
e. adding 20ul of CD14 magnetic beads into lymphocytes, incubating at 4 ℃ for 15min, adding 3ml of PBS, mixing uniformly, centrifuging at 3000rpm for 3min, and removing supernatant;
f. adding 2ml PBS, placing the LS column on a separation column, washing the column once by using 3ml PBS, and discarding the column washing liquid;
g. adding the cell resuspension solution into a separation column, collecting the effluent by using a new collecting tube, adding 2ml of PBS into the separation column, and continuously collecting the effluent, wherein the separated LS column and the combined cells can be discarded (CD14+ cells);
h. the collected CD 14-cells were centrifuged at 3000rpm for 3min, the supernatant was discarded, and the cells were resuspended in 80ul PBS.
3) Extraction of RNA
The total RNA of the cells was extracted from the sorted cells using an RNA extraction Kit (Rneasy MiNi Kit, 74104, qiagen, Germany), and the RNA concentration and quality were measured using nanodrop.
4) ARM-PCR amplification
Taking a proper amount of total RNA of cells as a template, and respectively carrying out reverse transcription and PCR amplification by using an HTCRI kit of iRepertore company in USA: amplification of the TRB-CDR3 region was amplified using HTCRI primers. The amplification system and conditions were as follows:
first PCR amplification system (table 2):
TABLE 2
| TRB-CDR3 | |
| 5×buffer | 5 |
| dNTP | 1 |
| Rnasin | 0.25 |
| Enzyme Mix | 1 |
| iRepertire primer | 4 |
| RNA | 100-1000ng |
| Ncclease-free H2O | Proper amount of |
| In total | 25ul |
First PCR amplification conditions for the TRB-CDR3 region (Table 3):
TABLE 3
Second PCR amplification system (table 4):
TABLE 4
Second PCR amplification conditions for the TRB-CDR3 region (Table 5):
TABLE 5
The PCR product of the TRB-CDR3 region is shown in FIG. 1, and its size is centered at 270-300 bp. The bands were excised and recovered, and each sample was quantified and checked for purity using agilent2100, and the PCR product was purified again if purity and concentration were not sufficient.
5) High throughput sequencing
a. Mixing equimolar amounts of 1 to 10 samples (samples obtained in step S4);
b. diluting the mixed sample by 1000 times, determining the concentration of the sample by using a KAPA second generation sequencing library quantitative kit, taking a reference sample Phix as a standard curve, and calculating the copy number of the sample according to the Ct value;
c. calculating the molar concentration of the mixed sample according to the size of the TRB-CDR3 fragment;
d. mixing 3.125uM of Phix internally participating in 9.375uM of a sample to be tested, modifying the mixture by NaOH for 5 minutes, and then adding HTX solution to ensure that the final volume is 1ml and the final concentration is 12.5 pM;
e. taking out a Miseq sequencing kit of Illumina company from a refrigerator at the temperature of-20 ℃, putting the Miseq sequencing kit into ice water until the Miseq sequencing kit is completely melted, and turning upside down for several times to uniformly mix liquid in the kit;
f. sucking 900ul of diluted sample to be detected, and adding the sample to be detected into a Miseq sequencing kit;
g. setting relevant parameters of a Miseq sequencer, and carrying out sequencing reaction;
h. and after about 40 hours, finishing the sequencing reaction, cleaning and maintaining the machine by using a 0.25% Triton 100 solution, and uploading the original data obtained by sequencing to a biological information server for storage and analysis.
6) Bioinformatics analysis
a. Decompressing the original data obtained by sequencing;
b. filtering out reads results without the communal sequence to obtain clean data of a sequencing result;
c. distinguishing different samples in the same lane according to the difference of the barcode sequence at the 5' end of the amplification primer used by each sample;
d. splicing reads matched with sequencing results at two ends in a sample into a complete read according to the principle of pair-end match;
e. performing blast alignment on the spliced sequence and information in an IMGT database (http:// www.imgt.org /), identifying the nucleotide sequences of the V region, the D region and the J region, and simultaneously translating into corresponding amino acid sequences;
f. screening the same read in a sample sequencing result, and finding out the frequency number of the same read and the number of the reads which encode the same protein although the cDNA of the read is different;
h. and counting the types and frequencies of different peptide fragments coded in the sample.
6) Data analysis
a. Grouping the samples according to the case information of the samples;
b. according to grouping results, the peptide fragments among all groups of samples are further analyzed and counted, and the method mainly comprises the following steps: the specific peptide fragments and the disease-related peptide fragments among the samples in the group are searched by comparing the data among the groups according to the existence and the frequency of the peptide fragments among the samples in the group.
7) Results of the study
TABLE 6 data of healthy pregnant women-TRB
| No.＝47 | Reads | CDR3 | Unique CDR3 | D50 | Age |
| Mean value of | 898750.33 | 888005.7619 | 8795.809524 | 3.857142857 | 30.48 |
| Standard deviation of | 387069.9562 | 382872.1054 | 10622.78292 | 4.825512556 | 2.758 |
| Standard of meritError of | 8235.530982 | 8146.215009 | 226.016658 | 0.10267048 | 0.068 |
TABLE 7 patients with gestational hypertension (blood pressure <160) -TRB
TABLE 8 gestational hypertensive patients (blood pressure >160) -TRB
8) Conclusion of the study
The TRB-CDR3 immune repertoire of the pregnant hypertensive has the characteristics that: 1) the number and the types of the CDR3 peptide segments have no obvious difference among healthy pregnant women, mild preeclampsia individuals and severe preeclampsia individuals; 2) the TRB-CDR3 immune group library is characterized by no obvious difference among healthy pregnant women, mild preeclampsia individuals and severe preeclampsia individuals; 3) the expression of some nucleotide or amino acid sequences is found to be highly related to the occurrence of pregnancy-induced hypertension through comparison, and the specific sequence, sensitivity and specificity are shown in the following table 9.
The sensitivity and specificity were calculated as follows:
four-grid table for diagnostic tests
| Case group | Non-case group | |||
| Diagnosis of | Positive for | (true positives) a | b (false positive) | a+b |
| Test of | Negative of | (false negative) c | d (true negative) | c+d |
| a+c | b+d | a+b+c+d |
Sensitivity (SEN) ═ a/(a + c)
Specificity (SPE) ═ d/(b + d)
Positive likelihood ratio (+ LR) ═ SEN/1-SPE
Negative likelihood ratio (-LR) ═ 1-SEN)/SPE
Accuracy a + d/(a + b + c + d)
Prevalence (i.e., pre-test probability) a + c/(a + b + c + d)
Pre-test odds (pre-disease odds) ((1-disease odds))
Post-test ratio (posr-test odds) — pre-test ratio × positive likelihood ratio
Post-test probability (post-test probability) (+ 1) post-test ratio/(post-test ratio)
TABLE 9
Example 2A method for diagnosing/screening pregnancy induced hypertension
A system for diagnosing pregnancy induced hypertension, comprising:
a. an input module: to input data information into the system, the data information being the TRB-CDR3 nucleotide sequence and/or amino acid sequence of the diagnostic subject;
b. a data comparison module: the data matching system is used for matching input data information with pre-stored data of the system, wherein the pre-stored data is relational data between one or more TRB-CDR3 sequences and pregnancy-induced hypertension risks;
c. a result output module: outputting the pregnancy hypertension risk data corresponding to the matching; when the input data information is matched with a certain pre-stored TRB-CDR3 sequence, the pregnancy period hypertension risk data corresponding to the pre-stored TRB-CDR3 sequence is the output result or the basis of the output result.
The data comparison module contains prestored data of SEQ ID NO: 30-59 TRB-CDR3 nucleotide sequence: and a polypeptide comprising SEQ ID NO: 60-89, and a TRB-CDR3 amino acid sequence.
The data on the relationship between the TRB-CDR3 sequence and the risk of gestational hypertension include data of groups 1 to 78 in Table 1.
The diagnosis/prediction/prognosis/screening of the pregnant hypertension patients by adopting the pregnant hypertension diagnosis system comprises the following steps:
1) peripheral blood of a diagnosis subject (pregnant person) was collected as in example 1;
2) peripheral blood cell separation as in example 1;
3) RNA was extracted as in example 1;
4) ARM-PCR amplification, as in example 1,
5) high throughput sequencing, as in example 1;
6) bioinformatics analysis is carried out to obtain a TRB-CDR3 immune library of a diagnosis object;
7) inputting the immune library of the diagnosis object into the diagnosis system of the invention for comparison, and outputting the illness risk value of the gestational hypertension by an output module of the diagnosis system according to the comparison result;
8) if the test subject is at risk for gestational hypertension, they are included in the observation or treatment regimen.
In this example, the selected diagnosis object (pregnant person) does not compare the results, and the output risk value is 0 (or no risk). The blood pressure of the diagnosis object is measured to be normal blood pressure, so that the diagnosis system has accuracy.
SEQUENCE LISTING
<110> institute of science and technology of the national institute of health and science and technology
<120> a diagnosis system for gestational hypertension
<130> PT20162123-DD-P
<160> 89
<170> PatentIn version 3.5
<210> 1
<211> 24
<212> DNA
<213> unknown
<400> 1
gcacaacagt tccctgactt gcac 24
<210> 2
<211> 24
<212> DNA
<213> unknown
<400> 2
tcatcaacca tgcaagcctg acct 24
<210> 3
<211> 24
<212> DNA
<213> unknown
<400> 3
gtctctagag agaagaagga gcgc 24
<210> 4
<211> 24
<212> DNA
<213> unknown
<400> 4
acatatgaga gtggatttgt catt 24
<210> 5
<211> 25
<212> DNA
<213> unknown
<400> 5
atacttcagt gagacacaga gaaac 25
<210> 6
<211> 24
<212> DNA
<213> unknown
<400> 6
ttccctaact atagctctga gctg 24
<210> 7
<211> 20
<212> DNA
<213> unknown
<400> 7
aggcctgagg gatccgtctc 20
<210> 8
<211> 22
<212> DNA
<213> unknown
<400> 8
cctgaatgcc ccaacagctc tc 22
<210> 9
<211> 24
<212> DNA
<213> unknown
<400> 9
atttacttta acaacaacgt tccg 24
<210> 10
<211> 24
<212> DNA
<213> unknown
<400> 10
cctaaatctc cagacaaagc tcac 24
<210> 11
<211> 24
<212> DNA
<213> unknown
<400> 11
ctccaaaaac tcatcctgta cctt 24
<210> 12
<211> 24
<212> DNA
<213> unknown
<400> 12
tcaacagtct ccagaataag gacg 24
<210> 13
<211> 18
<212> DNA
<213> unknown
<400> 13
aaaggagaag tctcagat 18
<210> 14
<211> 18
<212> DNA
<213> unknown
<400> 14
caaggagaag tccccaat 18
<210> 15
<211> 18
<212> DNA
<213> unknown
<400> 15
ggtgagggta caactgcc 18
<210> 16
<211> 24
<212> DNA
<213> unknown
<400> 16
gtctctcgaa aagagaagag gaat 24
<210> 17
<211> 24
<212> DNA
<213> unknown
<400> 17
agtgtctctc gacaggcaca ggct 24
<210> 18
<211> 24
<212> DNA
<213> unknown
<400> 18
aaagagtcta aacaggatga gtcc 24
<210> 19
<211> 21
<212> DNA
<213> unknown
<400> 19
cagatagtaa atgactttca g 21
<210> 20
<211> 24
<212> DNA
<213> unknown
<400> 20
gatgagtcag gaatgccaaa ggaa 24
<210> 21
<211> 24
<212> DNA
<213> unknown
<400> 21
caatgcccca agaacgcacc ctgc 24
<210> 22
<211> 24
<212> DNA
<213> unknown
<400> 22
agctctgagg tgccccagaa tctc 24
<210> 23
<211> 20
<212> DNA
<213> unknown
<400> 23
gattcacagt tgcctaagga 20
<210> 24
<211> 22
<212> DNA
<213> unknown
<400> 24
cagagaagtc tgaaatattc ga 22
<210> 25
<211> 21
<212> DNA
<213> unknown
<400> 25
gatcgattct cagctcaaca g 21
<210> 26
<211> 24
<212> DNA
<213> unknown
<400> 26
aaagatttta acaatgaagc agac 24
<210> 27
<211> 18
<212> DNA
<213> unknown
<400> 27
ttctgatggc tcaaacac 18
<210> 28
<211> 58
<212> DNA
<213> unknown
<400> 28
aatgatacgg cgaccaccga gatctacact ctttccctac acgacgctct tccgatct 58
<210> 29
<211> 61
<212> DNA
<213> unknown
<400> 29
caagcagaag acggcatacg agatcggtct cggcattcct gctgaaccgc tcttccgatc 60
t 61
<210> 30
<211> 36
<212> DNA
<213> unknown
<220>
<221> misc_feature
<222> (3)..(3)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (6)..(6)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (9)..(9)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (12)..(12)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (18)..(18)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (21)..(21)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (24)..(24)
<223> n is a, c, g, t or u
<400> 30
gcntcntcng gncarggntc ntcntaygar cartay 36
<210> 31
<211> 33
<212> DNA
<213> unknown
<220>
<221> misc_feature
<222> (3)..(3)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (6)..(6)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (9)..(9)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (15)..(15)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (18)..(18)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (21)..(21)
<223> n is a, c, g, t or u
<400> 31
gcntcntcnt tyggntcnac ntaygarcar tay 33
<210> 32
<211> 36
<212> DNA
<213> unknown
<220>
<221> misc_feature
<222> (3)..(3)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (6)..(6)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (9)..(9)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (12)..(12)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (15)..(15)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (18)..(18)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (21)..(21)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (24)..(24)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (30)..(30)
<223> n is a, c, g, t or u
<400> 32
gcntcntcnc tngcngtntc nggnaayacn athtay 36
<210> 33
<211> 36
<212> DNA
<213> unknown
<220>
<221> misc_feature
<222> (3)..(3)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (6)..(6)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (9)..(9)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (18)..(18)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (21)..(21)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (30)..(30)
<223> n is a, c, g, t or u
<400> 33
gcntcntcng arttytcngg naaycarccn carcay 36
<210> 34
<211> 39
<212> DNA
<213> unknown
<220>
<221> misc_feature
<222> (3)..(3)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (6)..(6)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (9)..(9)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (18)..(18)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (21)..(21)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (24)..(24)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (27)..(27)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (30)..(30)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (33)..(33)
<223> n is a, c, g, t or u
<400> 34
tcngcncgna arcarggntc nacntcnggn ccncarcay 39
<210> 35
<211> 30
<212> DNA
<213> unknown
<220>
<221> misc_feature
<222> (3)..(3)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (6)..(6)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (9)..(9)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (15)..(15)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (18)..(18)
<223> n is a, c, g, t or u
<400> 35
gcntcntcnc ayccnggnta ygarcartay 30
<210> 36
<211> 39
<212> DNA
<213> unknown
<220>
<221> misc_feature
<222> (3)..(3)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (6)..(6)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (9)..(9)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (15)..(15)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (18)..(18)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (21)..(21)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (24)..(24)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (27)..(27)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (33)..(33)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (36)..(36)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (39)..(39)
<223> n is a, c, g, t or u
<400> 36
gcntcntcnt tytcnggntc nggngcnaay gtnctnacn 39
<210> 37
<211> 33
<212> DNA
<213> unknown
<220>
<221> misc_feature
<222> (3)..(3)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (6)..(6)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (9)..(9)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (15)..(15)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (18)..(18)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (24)..(24)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (30)..(30)
<223> n is a, c, g, t or u
<400> 37
gcntcntcng arcgnctnaa yacngargcn tty 33
<210> 38
<211> 33
<212> DNA
<213> unknown
<220>
<221> misc_feature
<222> (3)..(3)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (6)..(6)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (9)..(9)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (15)..(15)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (21)..(21)
<223> n is a, c, g, t or u
<400> 38
gcntcntcnt tyccngartc ntaygarcar tay 33
<210> 39
<211> 33
<212> DNA
<213> unknown
<220>
<221> misc_feature
<222> (3)..(3)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (6)..(6)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (9)..(9)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (12)..(12)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (18)..(18)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (27)..(27)
<223> n is a, c, g, t or u
<400> 39
gcntcntcna cngaycgnaa ycarccncar cay 33
<210> 40
<211> 27
<212> DNA
<213> unknown
<220>
<221> misc_feature
<222> (3)..(3)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (6)..(6)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (9)..(9)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (12)..(12)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (15)..(15)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (18)..(18)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (24)..(24)
<223> n is a, c, g, t or u
<400> 40
gcntcncgng gnacnggnga rctntty 27
<210> 41
<211> 33
<212> DNA
<213> unknown
<220>
<221> misc_feature
<222> (3)..(3)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (6)..(6)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (9)..(9)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (12)..(12)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (15)..(15)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (18)..(18)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (21)..(21)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (27)..(27)
<223> n is a, c, g, t or u
<400> 41
gcntcntcnc gnggnggncg ngaracncar tay 33
<210> 42
<211> 33
<212> DNA
<213> unknown
<220>
<221> misc_feature
<222> (3)..(3)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (6)..(6)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (9)..(9)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (12)..(12)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (15)..(15)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (24)..(24)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (30)..(30)
<223> n is a, c, g, t or u
<400> 42
gcntcntcng gntcnatgaa yacngargcn tty 33
<210> 43
<211> 33
<212> DNA
<213> unknown
<220>
<221> misc_feature
<222> (3)..(3)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (6)..(6)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (9)..(9)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (18)..(18)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (21)..(21)
<223> n is a, c, g, t or u
<400> 43
gcntcntcnc argayctngg ntaygarcar tay 33
<210> 44
<211> 30
<212> DNA
<213> unknown
<220>
<221> misc_feature
<222> (3)..(3)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (6)..(6)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (9)..(9)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (12)..(12)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (15)..(15)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (18)..(18)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (24)..(24)
<223> n is a, c, g, t or u
<400> 44
gcntcntcnc tntcncgnga yacncartay 30
<210> 45
<211> 30
<212> DNA
<213> unknown
<220>
<221> misc_feature
<222> (3)..(3)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (6)..(6)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (9)..(9)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (15)..(15)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (18)..(18)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (24)..(24)
<223> n is a, c, g, t or u
<400> 45
gcntcntcnt tyggntcnga yacncartay 30
<210> 46
<211> 27
<212> DNA
<213> unknown
<220>
<221> misc_feature
<222> (3)..(3)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (6)..(6)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (9)..(9)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (18)..(18)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (21)..(21)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (24)..(24)
<223> n is a, c, g, t or u
<400> 46
gcntcntcng araaytcncc nctncay 27
<210> 47
<211> 36
<212> DNA
<213> unknown
<220>
<221> misc_feature
<222> (3)..(3)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (6)..(6)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (9)..(9)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (12)..(12)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (15)..(15)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (18)..(18)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (21)..(21)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (27)..(27)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (33)..(33)
<223> n is a, c, g, t or u
<400> 47
gcntcntcnc cnacnggnct naayacngar gcntty 36
<210> 48
<211> 33
<212> DNA
<213> unknown
<220>
<221> misc_feature
<222> (3)..(3)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (6)..(6)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (9)..(9)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (12)..(12)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (18)..(18)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (27)..(27)
<223> n is a, c, g, t or u
<400> 48
gcntcntcnc tngaycgnaa ycarccncar cay 33
<210> 49
<211> 30
<212> DNA
<213> unknown
<220>
<221> misc_feature
<222> (3)..(3)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (6)..(6)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (9)..(9)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (12)..(12)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (15)..(15)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (18)..(18)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (24)..(24)
<223> n is a, c, g, t or u
<400> 49
gcntcntcng gntcnacnga yacncartay 30
<210> 50
<211> 33
<212> DNA
<213> unknown
<220>
<221> misc_feature
<222> (3)..(3)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (6)..(6)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (9)..(9)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (12)..(12)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (15)..(15)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (18)..(18)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (24)..(24)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (30)..(30)
<223> n is a, c, g, t or u
<400> 50
gcntcntcnc tnacngcnaa yacngargcn tty 33
<210> 51
<211> 27
<212> DNA
<213> unknown
<220>
<221> misc_feature
<222> (3)..(3)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (6)..(6)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (9)..(9)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (12)..(12)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (21)..(21)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (27)..(27)
<223> n is a, c, g, t or u
<400> 51
gcntcntcnc tnaaytaygg ntayacn 27
<210> 52
<211> 30
<212> DNA
<213> unknown
<220>
<221> misc_feature
<222> (3)..(3)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (6)..(6)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (9)..(9)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (12)..(12)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (18)..(18)
<223> n is a, c, g, t or u
<400> 52
gcntcntcnt cncarggnta ygarcartay 30
<210> 53
<211> 30
<212> DNA
<213> unknown
<220>
<221> misc_feature
<222> (3)..(3)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (6)..(6)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (9)..(9)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (12)..(12)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (15)..(15)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (18)..(18)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (24)..(24)
<223> n is a, c, g, t or u
<400> 53
gcntcntcnt cntcnacnga yacncartay 30
<210> 54
<211> 33
<212> DNA
<213> unknown
<220>
<221> misc_feature
<222> (3)..(3)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (6)..(6)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (9)..(9)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (12)..(12)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (15)..(15)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (18)..(18)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (24)..(24)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (30)..(30)
<223> n is a, c, g, t or u
<400> 54
gcntcntcnc tncgnggnaa yacngargcn tty 33
<210> 55
<211> 33
<212> DNA
<213> unknown
<220>
<221> misc_feature
<222> (3)..(3)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (6)..(6)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (9)..(9)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (12)..(12)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (15)..(15)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (18)..(18)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (24)..(24)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (30)..(30)
<223> n is a, c, g, t or u
<400> 55
gcntcntcnc tnggngtnaa yacngargcn tty 33
<210> 56
<211> 27
<212> DNA
<213> unknown
<220>
<221> misc_feature
<222> (3)..(3)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (6)..(6)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (9)..(9)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (12)..(12)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (21)..(21)
<223> n is a, c, g, t or u
<400> 56
gcntcntcnt cncargarac ncartay 27
<210> 57
<211> 24
<212> DNA
<213> unknown
<220>
<221> misc_feature
<222> (3)..(3)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (6)..(6)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (9)..(9)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (18)..(18)
<223> n is a, c, g, t or u
<400> 57
gcntcntcnc argaracnca rtay 24
<210> 58
<211> 30
<212> DNA
<213> unknown
<220>
<221> misc_feature
<222> (3)..(3)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (6)..(6)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (9)..(9)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (12)..(12)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (15)..(15)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (18)..(18)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (24)..(24)
<223> n is a, c, g, t or u
<400> 58
gcntcntcnc cntcnacnga yacncartay 30
<210> 59
<211> 27
<212> DNA
<213> unknown
<220>
<221> misc_feature
<222> (3)..(3)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (6)..(6)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (9)..(9)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (12)..(12)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (15)..(15)
<223> n is a, c, g, t or u
<220>
<221> misc_feature
<222> (21)..(21)
<223> n is a, c, g, t or u
<400> 59
gcntcntcnc tngcngayac ncartay 27
<210> 60
<211> 12
<212> PRT
<213> unknown
<400> 60
Ala Ser Ser Gly Gln Gly Ser Ser Tyr Glu Gln Tyr
1 5 10
<210> 61
<211> 11
<212> PRT
<213> unknown
<400> 61
Ala Ser Ser Phe Gly Ser Thr Tyr Glu Gln Tyr
1 5 10
<210> 62
<211> 12
<212> PRT
<213> unknown
<400> 62
Ala Ser Ser Leu Ala Val Ser Gly Asn Thr Ile Tyr
1 5 10
<210> 63
<211> 12
<212> PRT
<213> unknown
<400> 63
Ala Ser Ser Glu Phe Ser Gly Asn Gln Pro Gln His
1 5 10
<210> 64
<211> 13
<212> PRT
<213> unknown
<400> 64
Ser Ala Arg Lys Gln Gly Ser Thr Ser Gly Pro Gln His
1 5 10
<210> 65
<211> 10
<212> PRT
<213> unknown
<400> 65
Ala Ser Ser His Pro Gly Tyr Glu Gln Tyr
1 5 10
<210> 66
<211> 13
<212> PRT
<213> unknown
<400> 66
Ala Ser Ser Phe Ser Gly Ser Gly Ala Asn Val Leu Thr
1 5 10
<210> 67
<211> 11
<212> PRT
<213> unknown
<400> 67
Ala Ser Ser Glu Arg Leu Asn Thr Glu Ala Phe
1 5 10
<210> 68
<211> 11
<212> PRT
<213> unknown
<400> 68
Ala Ser Ser Phe Pro Glu Ser Tyr Glu Gln Tyr
1 5 10
<210> 69
<211> 11
<212> PRT
<213> unknown
<400> 69
Ala Ser Ser Thr Asp Arg Asn Gln Pro Gln His
1 5 10
<210> 70
<211> 9
<212> PRT
<213> unknown
<400> 70
Ala Ser Arg Gly Thr Gly Glu Leu Phe
1 5
<210> 71
<211> 11
<212> PRT
<213> unknown
<400> 71
Ala Ser Ser Arg Gly Gly Arg Glu Thr Gln Tyr
1 5 10
<210> 72
<211> 11
<212> PRT
<213> unknown
<400> 72
Ala Ser Ser Gly Ser Met Asn Thr Glu Ala Phe
1 5 10
<210> 73
<211> 11
<212> PRT
<213> unknown
<400> 73
Ala Ser Ser Gln Asp Leu Gly Tyr Glu Gln Tyr
1 5 10
<210> 74
<211> 11
<212> PRT
<213> unknown
<400> 74
Ala Ser Ser Gln Asp Leu Gly Tyr Glu Gln Tyr
1 5 10
<210> 75
<211> 10
<212> PRT
<213> unknown
<400> 75
Ala Ser Ser Phe Gly Ser Asp Thr Gln Tyr
1 5 10
<210> 76
<211> 9
<212> PRT
<213> unknown
<400> 76
Ala Ser Ser Glu Asn Ser Pro Leu His
1 5
<210> 77
<211> 12
<212> PRT
<213> unknown
<400> 77
Ala Ser Ser Pro Thr Gly Leu Asn Thr Glu Ala Phe
1 5 10
<210> 78
<211> 11
<212> PRT
<213> unknown
<400> 78
Ala Ser Ser Leu Asp Arg Asn Gln Pro Gln His
1 5 10
<210> 79
<211> 10
<212> PRT
<213> unknown
<400> 79
Ala Ser Ser Gly Ser Thr Asp Thr Gln Tyr
1 5 10
<210> 80
<211> 10
<212> PRT
<213> unknown
<400> 80
Ala Ser Ser Gly Ser Thr Asp Thr Gln Tyr
1 5 10
<210> 81
<211> 9
<212> PRT
<213> unknown
<400> 81
Ala Ser Ser Leu Asn Tyr Gly Tyr Thr
1 5
<210> 82
<211> 10
<212> PRT
<213> unknown
<400> 82
Ala Ser Ser Ser Gln Gly Tyr Glu Gln Tyr
1 5 10
<210> 83
<211> 10
<212> PRT
<213> unknown
<400> 83
Ala Ser Ser Ser Ser Thr Asp Thr Gln Tyr
1 5 10
<210> 84
<211> 11
<212> PRT
<213> unknown
<400> 84
Ala Ser Ser Leu Arg Gly Asn Thr Glu Ala Phe
1 5 10
<210> 85
<211> 11
<212> PRT
<213> unknown
<400> 85
Ala Ser Ser Leu Arg Gly Asn Thr Glu Ala Phe
1 5 10
<210> 86
<211> 9
<212> PRT
<213> unknown
<400> 86
Ala Ser Ser Ser Gln Glu Thr Gln Tyr
1 5
<210> 87
<211> 8
<212> PRT
<213> unknown
<400> 87
Ala Ser Ser Gln Glu Thr Gln Tyr
1 5
<210> 88
<211> 10
<212> PRT
<213> unknown
<400> 88
Ala Ser Ser Pro Ser Thr Asp Thr Gln Tyr
1 5 10
<210> 89
<211> 9
<212> PRT
<213> unknown
<400> 89
Ala Ser Ser Leu Ala Asp Thr Gln Tyr
1 5
Claims (5)
1. A system for diagnosing pregnancy induced hypertension, the system comprising:
a. an input module: for inputting data information into the system, the data information being the TRB-CDR3 nucleotide sequence or amino acid sequence of the diagnostic subject;
b. a data comparison module: the data matching system is used for matching input data information with pre-stored data of the system, wherein the pre-stored data is relational data between one or more TRB-CDR3 sequences and pregnancy-induced hypertension risks; the TRB-CDR3 sequence is a nucleotide sequence or an amino acid sequence;
c. a result output module: outputting the pregnancy hypertension risk data corresponding to the matching; when the input data information is matched with a certain pre-stored TRB-CDR3 sequence, the pregnancy period hypertension risk data corresponding to the pre-stored TRB-CDR3 sequence is the output result or is used as the basis of the output result;
the pre-stored data in the data alignment module comprises one or more TRB-CDR3 nucleotide sequences, and/or comprises one or more TRB-CDR3 amino acid sequences; the TRB-CDR3 nucleotide sequence is shown in SEQ ID NO: 30-35; the TRB-CDR3 has an amino acid sequence shown in SEQ ID NO: 60-65;
when the input data information is matched with a certain pre-stored TRB-CDR3 sequence, outputting a result as having a risk or a risk value;
when the input data information does not match any pre-stored TRB-CDR3 sequence, the output result is no risk or low risk.
2. The diagnostic system of claim 1, wherein the relationship data between the TRB-CDR3 sequence and the risk of gestational hypertension necessarily contains one or more of the following sets of 1-6 data:
3. the diagnostic system of claim 1, further comprising a detection component; the detection component is used for determining the TRB-CDR3 nucleotide sequence or amino acid sequence of a diagnosis object.
4. The diagnostic system of claim 3, wherein the detecting means determines the TRB-CDR3 nucleotide sequence or amino acid sequence of the diagnostic object by one of genome and transcriptome level PCR, sequencing, DNA chip and protein chip.
5. The diagnostic system of claim 4, wherein said means for detecting obtains the TRB-CDR3 nucleotide sequence or amino acid sequence of the test subject using high throughput sequencing;
further, the detection method of the detection member includes the steps of:
s1, collecting peripheral blood of a pregnant woman;
s2, cell separation;
s3, RNA extraction;
s4, ARM-PCR amplification;
s5, high-throughput sequencing;
and S6, bioinformatics analysis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610981047.XA CN108070644B (en) | 2016-11-08 | 2016-11-08 | Diagnosis system for gestational hypertension |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610981047.XA CN108070644B (en) | 2016-11-08 | 2016-11-08 | Diagnosis system for gestational hypertension |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108070644A CN108070644A (en) | 2018-05-25 |
| CN108070644B true CN108070644B (en) | 2021-06-29 |
Family
ID=62154200
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610981047.XA Active CN108070644B (en) | 2016-11-08 | 2016-11-08 | Diagnosis system for gestational hypertension |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108070644B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1674931A (en) * | 2002-06-05 | 2005-09-28 | 贝勒医学院 | T cell receptor CDR3 sequences and methods for detection |
| CN103205420A (en) * | 2012-01-13 | 2013-07-17 | 深圳华大基因科技有限公司 | Primer composition for amplifying T cell receptor beta chain CDR3 coding sequence and application thereof |
| WO2015066379A2 (en) * | 2013-10-30 | 2015-05-07 | Genzyme Corporation | Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide |
| CN105087789A (en) * | 2015-08-10 | 2015-11-25 | 北京吉因加科技有限公司 | Method for detecting BCR and TCR immune repertoire in blood plasma cfDNA |
| WO2016138122A1 (en) * | 2015-02-24 | 2016-09-01 | Adaptive Biotechnologies Corp. | Methods for diagnosing infectious disease and determining hla status using immune repertoire sequencing |
-
2016
- 2016-11-08 CN CN201610981047.XA patent/CN108070644B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1674931A (en) * | 2002-06-05 | 2005-09-28 | 贝勒医学院 | T cell receptor CDR3 sequences and methods for detection |
| CN103205420A (en) * | 2012-01-13 | 2013-07-17 | 深圳华大基因科技有限公司 | Primer composition for amplifying T cell receptor beta chain CDR3 coding sequence and application thereof |
| WO2015066379A2 (en) * | 2013-10-30 | 2015-05-07 | Genzyme Corporation | Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide |
| WO2016138122A1 (en) * | 2015-02-24 | 2016-09-01 | Adaptive Biotechnologies Corp. | Methods for diagnosing infectious disease and determining hla status using immune repertoire sequencing |
| CN105087789A (en) * | 2015-08-10 | 2015-11-25 | 北京吉因加科技有限公司 | Method for detecting BCR and TCR immune repertoire in blood plasma cfDNA |
Non-Patent Citations (4)
| Title |
|---|
| Evidence for Superantigen Involvement in Preeclampsia;PATRIZIA LUPPI et al;《American Journal of Reproductive Immunology》;20000430;第43卷(第04期);第187页摘要，第188页右栏第2段，第193页表4 * |
| High-Throughput Sequencing Reveals Immunological Characteristics of the TRB-/IgH-CDR3 Region of Umbilical Cord Blood;Changlong Guo et al;《THE JOURNAL OF PEDIATRICS》;20160630;第176卷;第69-78页 * |
| PATRIZIA LUPPI et al.Evidence for Superantigen Involvement in Preeclampsia.《American Journal of Reproductive Immunology》.2000,第43卷(第04期),第187页摘要，第188页右栏第2段，第193页表4. * |
| 子痫前期患者外周血IGH-CDR3免疫组库的变化;郭昌龙 等;《中国计划生育学杂志》;20160331;第24卷(第03期);第160页摘要，第161页左栏第1段-第162页右栏第1段 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108070644A (en) | 2018-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104271759B (en) | Detection as the type spectrum of the same race of disease signal | |
| JP2015535178A (en) | Chronotype monitoring of plasma cell proliferation disorders in peripheral blood | |
| US10851415B2 (en) | Molecular predictors of sepsis | |
| CA2824854A1 (en) | Immunodiversity assessment method and its use | |
| WO2017059084A1 (en) | Immunorepertoire normality assessment method and its use | |
| CN106755464A (en) | For the method for screening the gene marker of intestinal cancer and/or stomach cancer, the gene marker and application thereof that is screened with the method | |
| CN110246539A (en) | A kind of method and device of immunity level assessment | |
| CN106399304B (en) | A kind of SNP marker relevant to breast cancer | |
| CN112176057A (en) | Marker for detecting pancreatic ductal adenocarcinoma by using CpG locus methylation level and application thereof | |
| WO2019117257A1 (en) | Method for assisting in detection of breast cancer | |
| CN104204223B (en) | For the method for the in-vitro diagnosis or prognosis of carcinoma of testis | |
| CN108070644B (en) | Diagnosis system for gestational hypertension | |
| CN108277277B (en) | Marker for evaluating familial breast cancer risk and application thereof | |
| CN108220416B (en) | Kit for detecting serum specific miRNA (micro ribonucleic acid) of constitution with yin deficiency and excessive internal heat and application of kit | |
| CN107002124A (en) | For the method for the survival prognosis for determining the patient with cancer of pancreas | |
| CN115873936A (en) | Biomarker CXCL8 and application thereof | |
| Jeon et al. | Transcriptomic profiles and their correlations in saliva and gingival tissue biopsy samples from periodontitis and healthy patients | |
| CN107488724B (en) | Peripheral blood circular RNA marker for noninvasive diagnosis of active tuberculosis and application | |
| CN106636351B (en) | One kind SNP marker relevant to breast cancer and its application | |
| CN104024434B (en) | In-vitro diagnosis or the method for prognosis for carcinoma of prostate | |
| CN111933216B (en) | Use of intestinal microorganisms as preeclampsia biomarkers | |
| CN111996248B (en) | Reagent for detecting microorganism and application thereof in diagnosis of myasthenia gravis | |
| RU2777487C1 (en) | Method for assessment of risk of necessity of use of oxygen therapy in covid-19 | |
| CN112226501B (en) | Intestinal flora marker for myasthenia gravis and application thereof | |
| CN117551753A (en) | Autoimmune hepatitis biomarker |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |